军事知识服务平台
CXCL8在1型糖尿病胰岛炎症中对巨噬细胞STAT1-IFN-Ⅰ信号轴的调控作用
Regulation of the macrophage STAT1-IFN-I signaling axis by CXCL8 during islet inflammation in type 1 diabetes
摘要 目的:探讨巨噬细胞来源的C-X-C基序趋化因子配体8(CXCL8)在1型糖尿病(T1DM)胰岛炎症中对STAT1-IFN-Ⅰ信号轴的调控作用。方法:基于GEO数据库人胰岛转录组数据集(GSE102371、GSE108413)及PANCDB单细胞测序数据筛选T1DM免疫相关差异基因。收集南京医科大学附属儿童医院2023年10月至2026年1月57例T1DM患儿和37名健康对照儿童的外周血,以及1名健康人胰岛组织。采用定量PCR检测人胰岛、THP-1细胞及外周血单个核细胞(PBMC)中 CXCL8及相关基因的mRNA表达,ELISA检测血清CXCL8水平,Western blotting检测THP-1细胞中STAT1总蛋白及Y701位点磷酸化水平。利用慢病毒过表达THP-1细胞中 CXCL8并联合转录组测序分析其功能。采用线性回归模型评估血清 CXCL8与空腹血糖(FPG)、糖化血红蛋白(HbA 1c)、C肽(CP)和胰岛素的相关性,并校正年龄、性别和糖尿病病程,绘制受试者工作特征(ROC)曲线评估其诊断价值。 结果:57例T1DM患儿年龄(8.7±3.4)岁,男27例(47.4%),女30例(52.6%);37名健康对照年龄(8.1±2.9)岁,男20名(54.1%),女17名(45.9%)。单细胞测序数据显示, CXCL8主要表达于胰岛巨噬细胞,T1DM患者胰岛巨噬细胞中 CXCL8的表达水平高于健康对照组( P<0.01)。T1DM患儿PBMC中 CXCL8 mRNA表达(10.56±2.01比1.00±0.23, P<0.001)及血清 CXCL8水平( P<0.001)均高于健康对照组。体外实验显示,过表达 CXCL8可增强IFN-α诱导的STAT1 Y701位点磷酸化及STAT1总蛋白表达,并上调干扰素刺激基因 IFIT3、 IFIT2、 IFI6、 MX1、 IFI44L、 OASL、 EPSTI1和 ISG15的表达(均 P<0.05);上述基因在T1DM患儿PBMC中的表达亦高于健康对照组(均 P<0.05)。血清 CXCL8与FPG( B=8.45,95%CI 3.78~13.12, P<0.001)及HbA 1c( B=7.11,95%CI 4.97~9.25, P<0.001)呈正相关,与CP( B=-0.17,95%CI -0.32~-0.01, P=0.044)及胰岛素( B=-7.32,95%CI -13.50~-0.86, P=0.031)呈负相关。血清 CXCL8诊断T1DM的ROC曲线下面积为0.925(95%CI 0.861~0.989),灵敏度100%,特异度83.3%。 结论:CXCL8可能通过激活巨噬细胞STAT1-IFN-Ⅰ信号通路参与胰岛炎症和T1DM疾病进展,并具有作为T1DM生物标志物的潜力。
Abstract:
Objective:To investigate the regulatory effect of the macrophage-derived C-X-C motif chemokine ligand 8 (CXCL8) on the STAT1-IFN-Ⅰ signaling axis during islet inflammation in type 1 diabetes mellitus (T1DM).Methods:T1DM immune-related differentially expressed genes were identified using human islet transcriptome datasets (GSE102371, GSE108413) from the GEO database and PANCDB single-cell sequencing datasets. Peripheral blood samples were collected from 57 children with T1DM and 37 healthy control children at the Children's Hospital affiliated to Nanjing Medical University from October 2023 to January 2026. Islet tissue was also collected from one healthy individual. Quantitative PCR was used to detect mRNA expression of CXCL8 and related genes in human islets, THP-1 cells, and peripheral blood mononuclear cell (PBMC). ELISA was used to measure serum CXCL8 levels, and Western blotting was used to detect total STAT1 protein expression and phosphorylation at the Y701 site in THP-1 cells. Lentivirus-mediated overexpression of CXCL8 in THP-1 cells combined with transcriptome sequencing was used to analyze its function. Linear regression models were used to evaluate the associations of serum CXCL8 with fasting plasma glucose (FPG), glycated hemoglobin (HbA 1c), C-peptide (CP), and insulin, adjusting for age, sex, and diabetes duration. Receiver operating characteristic (ROC) curves were constructed to assess diagnostic value. Results:A total of 57 T1DM children had a mean age of (8.7±3.4) years, and included 27 males (47.4%) and 30 females (52.6%). The 37 healthy controls had a mean age of (8.1±2.9) years, and included 20 males (54.1%) and 17 females (45.9%). Single-cell sequencing data showed that CXCL8 was mainly expressed in islet macrophages, with higher expression in patients with T1DM than in healthy controls ( P<0.01). CXCL8 mRNA expression in PBMC of T1DM children was higher than that of healthy controls (10.56±2.01 vs. 1.00±0.23, P<0.001), and serum CXCL8 levels were also elevated ( P<0.001). In vitro experiments demonstrated that CXCL8 overexpression enhanced IFN-α-induced phosphorylation at STAT1 Y701 and total STAT1 protein expression, and upregulated the expression of interferon-stimulated genes IFIT3, IFIT2, IFI6, MX1, IFI44L, OASL, EPSTI1, and ISG15 (all P<0.05); the expression of these genes was also higher in PBMC of T1DM children than in controls (all P<0.05). Serum CXCL8 was positively correlated with FPG ( B=8.45, 95%CI 3.78-13.12, P<0.001) and HbA 1c ( B=7.11, 95%CI 4.97-9.25, P<0.001), and negatively correlated with CP ( B=-0.17, 95%CI -0.32 to -0.01, P=0.044) and insulin ( B=-7.32, 95%CI -13.50 to -0.86, P=0.031). The area under the ROC curve of serum CXCL8 for diagnosing T1DM was 0.925 (95%CI 0.861-0.989), with a sensitivity of 100% and specificity of 83.3%. Conclusions:CXCL8 may contribute to islet inflammation and T1DM progression by activating the macrophage STAT1-IFN-Ⅰ signaling pathway and has potential as a biomarker for T1DM.